# COPD Exacerbations and Acute Management

## Definition and Classification

### GOLD 2024 Definition

A COPD exacerbation is defined as an acute worsening of respiratory symptoms, including dyspnea, cough, and changes in sputum volume or purulence, that extends beyond normal day-to-day variation and leads to a change in medication. This definition, while clinically practical, has been criticized for its subjectivity. The new Rome proposal by Celli and colleagues in 2023 aims to introduce more objective diagnostic criteria, requiring the presence of dyspnea along with at least one of the following: increased sputum purulence, increased sputum volume, tachypnea at or above 24 breaths per minute, tachycardia at or above 95 beats per minute, SpO2 below 92% on room air, or CRP at or above 10 mg/L. This objectification of the exacerbation definition may improve diagnostic consistency and clinical trial design. Exacerbations carry profound consequences beyond the acute episode: they accelerate the rate of FEV1 decline, significantly worsen quality of life, increase subsequent mortality risk, and are the primary driver of COPD-related healthcare costs.

### Severity Classification (GOLD 2024)

| Severity | Management Level | Treatment |
|----------|-----------------|-----------|
| Mild | Outpatient | Short-acting bronchodilators alone |
| Moderate | Outpatient | SABA + antibiotics and/or oral corticosteroids |
| Severe | Hospitalization / ED | IV/nebulized bronchodilators, steroids, antibiotics, +/- NIV |
| Very Severe | ICU | Mechanical ventilation (invasive or non-invasive) |

GOLD 2024 classifies exacerbation severity into four tiers. Mild exacerbations are managed with short-acting bronchodilators alone. Moderate exacerbations require short-acting bronchodilators plus antibiotics and/or oral corticosteroids. Severe exacerbations necessitate hospitalization or emergency department evaluation. Very severe exacerbations require ICU admission or mechanical ventilation. This classification guides treatment intensity and disposition decisions.

### Etiology of Exacerbations

The etiologic landscape of COPD exacerbations reflects a complex interplay of infectious and non-infectious triggers. Viral infections account for 30-50% of exacerbations, with rhinovirus being the most commonly identified pathogen, followed by influenza, parainfluenza, and respiratory syncytial virus. Bacterial infections contribute to another 30-50% of exacerbations; the predominant community-acquired organisms include Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. In patients with severe COPD (FEV1 below 30%), recurrent antibiotic courses, bronchiectasis overlap, or recent hospitalization, Pseudomonas aeruginosa and Enterobacteriaceae assume greater importance. Environmental triggers including air pollution (PM2.5, ozone) and temperature extremes can precipitate exacerbations. Non-infectious mimics must always be considered, particularly pulmonary embolism (found in 15-25% of patients undergoing CTPA during unexplained severe exacerbations), pneumothorax, and cardiac decompensation. Eosinophilic exacerbations, identified by blood eosinophils at or above 300 at presentation, may respond more robustly to systemic corticosteroids.

## Assessment of the Exacerbation

### Initial Evaluation

Systematic evaluation of the patient presenting with a COPD exacerbation begins with a focused history that establishes the patient's baseline functional status (mMRC dyspnea scale), prior exacerbation frequency, prior episodes requiring intubation or non-invasive ventilation, home oxygen use, and current medication regimen. Physical examination should assess respiratory rate, accessory muscle use, ability to speak in sentences, presence of paradoxical breathing (which suggests diaphragmatic fatigue and impending respiratory failure), mental status, and peripheral edema suggestive of cor pulmonale. Oxygen saturation should target 88-92%, with particular care to avoid excessive supplemental oxygen in patients known to be CO2 retainers. Arterial blood gas analysis is indicated when SpO2 falls below 92%, hypercapnia is suspected, or the exacerbation is severe, as the pH measurement directly drives the decision regarding non-invasive ventilation. Chest radiography should be performed to exclude pneumonia, pneumothorax, pleural effusion, and pulmonary edema. An ECG screens for arrhythmia, right heart strain, and ischemia. Laboratory investigations should include CBC (for eosinophil count and white cell count), CRP or procalcitonin, basic metabolic panel, and BNP if cardiac comorbidity is suspected.

### Differential Diagnosis to Exclude

A systematic approach to differential diagnosis prevents misattribution of symptoms to COPD exacerbation. Acute decompensated heart failure should be assessed with BNP or NT-proBNP and point-of-care ultrasound. Pneumonia may require CT imaging when the chest radiograph is equivocal. Pulmonary embolism should be considered with CTPA when unexplained hypoxemia, pleuritic pain, or additional risk factors are present, given the significant prevalence of 15-25% in unexpected exacerbation presentations. Pneumothorax, while less common, occurs more frequently in emphysematous patients. Acute coronary syndrome should be evaluated with ECG and troponin testing.

<image>A clinical assessment algorithm for acute COPD exacerbation in the emergency department. Start with initial assessment (vitals, SpO2, mental status, work of breathing). First branch: life-threatening features (impending respiratory arrest, GCS < 12, hemodynamic instability) leading to ICU and consideration of intubation. Second branch: severe features (RR > 30, accessory muscle use, unable to speak in sentences, pH 7.25-7.35) leading to NIV + medical management. Third branch: mild-moderate features (able to speak, RR < 30, SpO2 > 88% on low-flow O2) leading to bronchodilators + steroids +/- antibiotics. Include investigation boxes at each level: ABG indications, CXR, ECG, lab work with specific thresholds. Show disposition decision points: discharge criteria, ward admission criteria, ICU criteria.</image>

## Pharmacologic Management

### Bronchodilators

Initial bronchodilator therapy consists of a short-acting beta-agonist (SABA), typically salbutamol 2.5-5 mg nebulized every 20 minutes for three doses, then every 1 to 4 hours as needed, or alternatively 4-8 puffs via MDI with spacer every 20 minutes. A short-acting anticholinergic, ipratropium 500 mcg nebulized every 4-6 hours, is commonly combined with the SABA for additive bronchodilation. Cochrane evidence has demonstrated that MDI with spacer is equally effective to nebulizer delivery in non-ICU patients, and the choice should be guided by patient ability and preference. There is no role for intravenous aminophylline or theophylline in the management of acute exacerbations, as these agents increase side effects without providing proven benefit.

### Systemic Corticosteroids

Systemic corticosteroids remain a cornerstone of moderate-to-severe exacerbation management. The REDUCE trial established that a 5-day course of prednisone 40 mg daily is non-inferior to the traditional 14-day course, and this shorter regimen should be adopted as standard practice. Intravenous methylprednisolone 40 mg every 12 hours is appropriate for patients unable to take oral medications or those who are critically ill. The benefits of corticosteroids include faster FEV1 recovery, shorter hospital stays, and reduced treatment failure at 30 days. Emerging evidence supports the use of blood eosinophils at presentation to guide corticosteroid therapy. Patients with eosinophils at or above 300 demonstrate strong benefit from systemic corticosteroids, while those with eosinophils below 100 may not benefit, as explored in the CORTICO-COP trial. Eosinophil-guided corticosteroid therapy remains an active area of investigation.

### Antibiotics

| Setting | Regimen | Dose | Duration | Key Indications |
|---------|---------|------|----------|-----------------|
| Outpatient / mild-moderate | Amoxicillin-clavulanate | 875/125 mg PO BID | 5–7 days | Increased sputum purulence + dyspnea or volume (Anthonisen Type 1) |
| Outpatient / mild-moderate | Doxycycline | 100 mg PO BID | 5 days | Alternative first-line |
| Outpatient / mild-moderate | Azithromycin | 500 mg day 1, then 250 mg | 5 days | Alternative; caution QTc |
| Severe / Pseudomonas risk | Piperacillin-tazobactam | 4.5 g IV q6h | 5–7 days | FEV1 < 30%, prior Pseudomonas, bronchiectasis, recent hospitalization |
| Severe / Pseudomonas risk | Ciprofloxacin (oral) | 750 mg PO BID | 7 days | Oral anti-pseudomonal option |
| Severe / Pseudomonas risk | Levofloxacin | 750 mg PO/IV daily | 5–7 days | Oral/IV anti-pseudomonal option |

Antibiotics are indicated when increased sputum purulence is accompanied by increased dyspnea or sputum volume (fulfilling Anthonisen Type 1 criteria), or when the patient requires mechanical ventilation. For outpatient or mild-to-moderate exacerbations, appropriate regimens include amoxicillin-clavulanate 875/125 mg twice daily for 5-7 days, doxycycline 100 mg twice daily for 5 days, or azithromycin 500 mg on day 1 followed by 250 mg for 4 days. For severe exacerbations or when Pseudomonas risk factors are present (severe COPD with FEV1 below 30%, prior Pseudomonas isolation, frequent antibiotic use of 4 or more courses per year, bronchiectasis, recent hospitalization), coverage should be broadened with piperacillin-tazobactam 4.5 g IV every 6 hours, or oral ciprofloxacin 750 mg twice daily or levofloxacin 750 mg daily. Procalcitonin-guided antibiotic therapy reduces antibiotic exposure without worsening outcomes, as demonstrated in the ProCOPD trial. A treatment duration of 5-7 days is sufficient for most exacerbations.

### Oxygen Therapy

Oxygen delivery in acute COPD exacerbation must be carefully titrated. The target SpO2 of 88-92% is supported by the Austin et al. Lancet 2010 study, which demonstrated that mortality was reduced with titrated oxygen compared to high-flow oxygen in the prehospital setting. Venturi masks are preferred for precise FiO2 delivery, offering settings at 24%, 28%, 31%, 35%, and 40%. Standard nasal cannula at 1-2 L/min typically achieves 24-28% FiO2 but with less precision. Hyperoxia must be avoided as it causes harm through three mechanisms: suppression of the hypoxic ventilatory drive, the Haldane effect (oxygen-induced displacement of CO2 from hemoglobin, raising PaCO2), and absorption atelectasis.

## Non-Invasive Ventilation (NIV)

### Indications

Non-invasive ventilation is indicated for respiratory acidosis (pH below 7.35 with PaCO2 above 45 mmHg) persisting despite initial bronchodilator therapy, severe dyspnea with clinical signs of respiratory muscle fatigue, and persistent hypoxemia despite supplemental oxygen. The pH threshold drives the decision to initiate NIV, making ABG assessment central to acute management.

### Evidence Base

The evidence supporting NIV in acute hypercapnic COPD exacerbation is among the strongest in critical care medicine. The Cochrane 2017 meta-analysis demonstrated that NIV reduces the intubation rate (relative risk 0.41), ICU length of stay, and hospital mortality (relative risk 0.52). The number needed to treat to prevent one intubation is approximately 4, and the number needed to treat to prevent one death is approximately 10. These figures represent exceptional efficacy for any acute care intervention.

### Practical Application

BiPAP should be initiated at IPAP 10-12 cmH2O and EPAP 4-5 cmH2O, with IPAP titrated upward by 2 cmH2O every 15-30 minutes, targeting a tidal volume of 6-8 mL/kg, respiratory rate below 25, and demonstrable improvement in pH. Typical effective settings range from IPAP 14-20 cmH2O and EPAP 4-6 cmH2O. An oronasal mask is preferred for acute applications, and proper fit with minimal leak is essential for efficacy. ABG should be reassessed at 1-2 hours after NIV initiation; failure to improve pH should prompt consideration of escalation to invasive mechanical ventilation. Contraindications include cardiac or respiratory arrest, inability to protect the airway, facial trauma or surgery, gastrointestinal bleeding with hematemesis, and hemodynamic instability.

### NIV Failure Predictors

Several factors predict NIV failure and should prompt heightened vigilance. A pH below 7.25 at presentation identifies patients at high risk of failure, though a trial of NIV should still be attempted with intubation equipment at the ready. Failure to improve pH after 1-2 hours of optimized NIV is perhaps the most important predictor and should trigger escalation planning. A Glasgow Coma Scale below 11 represents a relative contraindication, though some evidence supports NIV use in mild encephalopathy with close monitoring. An APACHE II score above 29 also predicts poor response to NIV.

<image>A side-by-side comparison diagram of NIV settings and management for COPD exacerbation. Left panel: initial setup showing machine (BiPAP), mask selection (oronasal), initial settings (IPAP 10-12, EPAP 4-5, backup rate 12-14, FiO2 to target SpO2 88-92%). Right panel: titration algorithm over time - reassess at 30 min, 1 hour, 2 hours with ABG. Show decision nodes: pH improving (continue, wean), pH unchanged (increase IPAP by 2), pH worsening (consider intubation). Include a box listing contraindications and failure predictors. Bottom section: weaning protocol showing gradual reduction of IPAP, daytime NIV holidays, transition to spontaneous breathing.</image>

## Intubation and Mechanical Ventilation

### Indications for Intubation

Intubation is indicated for NIV failure or contraindication, respiratory or cardiac arrest, severe hemodynamic instability, inability to protect the airway (GCS below 8, copious secretions), and refractory hypoxemia despite escalating non-invasive support.

### Ventilator Strategy in COPD

The primary ventilatory challenge in mechanically ventilated COPD patients is minimizing dynamic hyperinflation, also known as auto-PEEP or intrinsic PEEP. The ventilator strategy should employ a low respiratory rate (10-14 breaths per minute) with prolonged expiratory time (I:E ratio of 1:3 to 1:5) to allow complete exhalation before the next breath. Tidal volumes of 6-8 mL/kg ideal body weight are appropriate. Minute ventilation should be reduced to the extent tolerable, with permissive hypercapnia accepted as long as the pH remains above 7.20. External PEEP should be set at approximately 80% of the measured auto-PEEP to reduce the work of breathing required to trigger the ventilator and facilitate synchronous triggering. Plateau pressure should be maintained below 30 cmH2O, and auto-PEEP should be measured regularly using end-expiratory holds.

## Discharge Planning and Prevention

### Discharge Criteria

Patients should meet specific readiness criteria before discharge: SABA use no more frequent than every 4 hours, ability to eat and sleep without significant dyspnea, clinical stability for at least 12-24 hours, SpO2 at or above 88% on room air or the patient's prior home oxygen prescription, adequate patient and caregiver education on medication use and action plans, and follow-up arranged within 1-4 weeks. Maintenance inhaler therapy should be reviewed and optimized before discharge.

### Exacerbation Prevention Strategies

A comprehensive prevention strategy significantly reduces the burden of future exacerbations. Smoking cessation reduces exacerbation risk by 30-40%. Pulmonary rehabilitation initiated within 2-4 weeks of discharge reduces readmission, as demonstrated in Cochrane reviews. Maintenance therapy should be optimized with LABA/LAMA with or without ICS guided by eosinophil levels. Prophylactic azithromycin (250 mg daily or 500 mg three times weekly) reduces exacerbations by 25-30%, as demonstrated in the MACRO trial, though risks include hearing impairment, QTc prolongation, and antimicrobial resistance, and NTM must be excluded before initiation. Roflumilast is indicated for the chronic bronchitis phenotype with FEV1 below 50% and recurrent exacerbations. Comprehensive vaccination should be ensured. Self-management action plans providing early antibiotics and prednisone for symptom worsening reduce the incidence of severe exacerbations.

## Key Clinical Pearls

- Target SpO2 88-92% in acute COPD exacerbation; uncontrolled high-flow oxygen increases mortality (Austin et al.)
- A 5-day course of prednisone 40 mg is as effective as 14 days (REDUCE trial) and should be standard practice
- Blood eosinophils at presentation help guide corticosteroid use: eos >= 300 predicts corticosteroid-responsive exacerbation; eos < 100 may not benefit
- NIV is the standard of care for acute hypercapnic respiratory failure in COPD (pH < 7.35); NNT to prevent intubation is approximately 4
- Always consider PE as a cause of COPD exacerbation, especially if hypoxemia is disproportionate to airflow obstruction or pleuritic pain is present (prevalence 15-25% in unexplained exacerbations)

## References
1. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: The REDUCE Randomized Clinical Trial. JAMA. 2013;309(21):2223-2231.
2. Osadnik CR, Tee VS, Carson-Chahhoud KV, et al. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;7(7):CD004104.
3. Albert RK, Connett J, Bailey WC, et al. Azithromycin for Prevention of Exacerbations of COPD. N Engl J Med. 2011;365(8):689-698. (MACRO)
4. Austin MA, Wills KE, Blizzard L, et al. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010;341:c5462.
5. Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019;7(8):699-709.